Search results
Thousands of dollars raised for Epilepsy Association during fundraiser in Pittsburgh
WPXI· 6 days agoA fundraiser was held in Pittsburgh on Saturday to help people with epilepsy. The 36th Annual Family...
Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $1.20
ETF DAILY NEWS· 2 days agoOvid Therapeutics (NASDAQ:OVID – Get Free Report) had its price target reduced by investment analysts at Citigroup from $3.50 to $1.20 in a research note issued on Tuesday, Benzinga reports.
Takeda's seizure drug fails to meet main goal in late-stage studies
Reuters· 4 days agoJapan's Takeda said on Monday its experimental drug to treat epileptic disorders failed to meet the...
Takeda drug for rare types of epilepsy misses goal in late-stage trial
BioPharma Dive via Yahoo Finance· 4 days agoCalled soticlestat, the drug had seemed promising in earlier studies for people with Dravet and...
Takeda’s seizure drug fails to meet main goal in late-stage studies
KFGO· 4 days ago(Reuters) - Japan's Takeda said on Monday its experimental drug to treat epileptic disorders failed...
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Zacks via Yahoo Finance· 1 day agoIntra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight...
Pyros wins FDA approval for ready-to-use infantile spasm treatment
Pharmaceutical Technology via Yahoo Finance· 3 days agoInfantile spasms usually begin in children aged one year or less and can lead to long-term...
Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $3.00
ETF DAILY NEWS· 2 days agoOvid Therapeutics (NASDAQ:OVID – Get Free Report) had its price target reduced by equities research analysts at B. Riley from $9.00 to $3.00 in a report issued on Tuesday, Benzinga reports.
William Blair Research Analysts Boost Earnings Estimates for Ovid Therapeutics Inc. (NASDAQ:OVID)
ETF DAILY NEWS· 2 days agoOvid Therapeutics Inc. (NASDAQ:OVID – Free Report) – Equities research analysts at William Blair raised their Q2 2025 earnings per share estimates for shares of Ovid Therapeutics in a research ...
Oppenheimer Lowers Ovid Therapeutics (NASDAQ:OVID) to Market Perform
ETF DAILY NEWS· 3 days agoOvid Therapeutics (NASDAQ:OVID – Get Free Report) was downgraded by stock analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a report issued on Tuesday, Briefing.com ...